antide

Antide has a wide range of applications in life science related research.

Antide acetate is an LHRH antagonist and represses LH and FSH release from the pituitary gland.

Antidepressant agent 10 ,with CAS No. 87691-87-0, is a fragment molecule that serves as an important scaffold for molecular linking, expansion, and modification. Antidepressant agent 10 provides a structural basis and research tool for the design and screening of novel drug candidates, and is commonly used in drug discovery, drug synthesis, and related research.

Galantide acetate, a non-specific galanin receptor antagonist, is a peptide consisting of fragments of galanin and substance P. Galantide acetate recognizes two classes of galanin binding sites (KD<0.1 nM and ~6 nM) in the rat hypothalamus. Galantide acetate dose dependently (IC50=1.0 nM) antagonizes the galanin-mediated inhibition of the glucose-induced insulin secretion from mouse pancreatic islets. Galantide acetate appears to bind to a single population of SP receptors (KD~40 nM).

Antidepressant agent 5 is a 7-substituted tetrahydroisoquinoline derivative with antidepressant activity.Antidepressant agent 5 acts similarly to magnoflorine in the study of depression and can be used for the prevention and treatment of depressive disorders.

Malantide acetate is a dodecapeptide phosphorylated by cyclic AMP-dependent protein kinase (PKA), and increases PKA activity.Malantide is a synthetic peptide that is phosphorylated by PKA and is used to measure PKA activity in vitro.

Antidepressant agent 1, a pyrazidole-halogeno-derivative, exhibits antidepressant effects and can also be used to increase body temperature.

Galantide is a reversible and non-specific antagonist of galanin receptor.

Antidesmone is one compound mainly isolated from Ajugade cumbers Thunb (Labiatae). Antidesmone prevents acute lung injury via regulating MAPK and NF-κB activities.

Spantide antagonizes both bombesin & substance P. It is also tachykinin receptor antagonist.

Spantide acetate is a selective antagonist of NK1 receptor with Kis of 230 nM and 8150 nM for NK1 and NK2.

Antidepressant agent 8 (Compound 1f) acts as a selective antagonist for the NMDA receptor GluN1/2A (NMDA receptorGluN1/2A), with an IC50 of 2.94 μmol/L. In a hydrocortisone-induced zebrafish depression model, it demonstrates antidepressant-like effects and shows good blood-brain barrier penetration.

Analgesic/antidepressant agent-1 (Compound k1) is an orally active N-acetylamino chloro ketone derivative capable of crossing the blood-brain barrier. It exhibits high affinity for NMDA receptors and demonstrates analgesic, anti-inflammatory, and antidepressant properties, with low psychotomimetic activity.

Antidepressant agent 9 (Compound 24) is an orally active inhibitor of NMDAR and SERT, with IC50 values of 3.50 μM and 1044 nM, respectively. It exhibits good metabolic stability and plasma exposure, and demonstrates antidepressant-like effects in the forced swim test in mice.

Antidepressant agent 6 (S-3a) is a lead compound demonstrating potent and enduring antidepressant effects. It has shown high cognitive safety, antagonizes the M1 receptor, and elevates BDNF levels, making it valuable for depression research.

Antidepressant agent 2 showed significant antidepressant effects with a MED value of 0.1 mg/kg.

Antidepressant agent 3, an orally active compound, showcases multifaceted pharmacological properties including antidepressant, anxiolytic, performance-enhancing, and nootropic activities [1].

Antidepressant agent 4, an orally active compound, demonstrates efficacy as an antidepressant with additional anxiolytic, performance-enhancing, and nootropic activities [1].

Galantide TFA, a reversible and non-specific antagonist of the galanin (GAL) receptor, demonstrates dose-dependent inhibition of galanin-induced K+ conductance, exhibiting an IC50 value of 4 nM. It is utilized in neurological disease and hormone metabolism research [1] [2].

Spantide I TFA, a selective NK1 receptor antagonist and a substance P analog, exhibits K(i) values of 230 nM for NK1 and 8150 nM for NK2 receptors, respectively. It offers a method to decrease type 1 while increasing type 2 cytokine IL-10 in the infected cornea, significantly reducing corneal perforation [1] [2] [3].

Malantide TFA, a synthetic dodecapeptide, originates from the phosphorylation site targeted by cAMP-dependent protein kinase (PKA) on the β-subunit of phosphorylase kinase. Exhibiting a high specificity for PKA with a Michaelis constant (Km) of 15 μM, this compound demonstrates more than 90% inhibition of substrate phosphorylation in the presence of protein inhibitor (PKI) across various rat tissue extracts [1]. Moreover, Malantide TFA acts as an effective substrate for Protein Kinase C (PKC) with a Km of 16 μM [2].

Ecallantide (DX-88), a recombinant inhibitor targeting plasma kallikrein, impedes bradykinin synthesis and is used to prevent acute episodes of angioedema [1].

[D-Pro2] Spantide I TFA is an analog of Spantide I, serving as a selective antagonist of the NK1 receptor [1].

Irucalantide is a kallikrein inhibitor [1].